Details

Autor(en) / Beteiligte

• Kawagishi, Naoki
• Suda, Goki
• Yamamoto, Yoshiya
• Baba, Masaru
• Furuya, Ken
• Maehara, Osamu
• Ohnishi, Shunsuke
• Yoshida, Sonoe
• Fu, Qingjie
• Yang, Zijian
• Hosoda, Shunichi
• Tokuchi, Yoshimasa
• Kitagataya, Takashi
• Ohara, Masatsugu
• Suzuki, Kazuharu
• Nakai, Masato
• Sho, Takuya
• Natsuizaka, Mitsuteru
• Ogawa, Koji
• Sakamoto, Naoya

Titel

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

Ist Teil von

• Viruses, 2023-01, Vol.15 (1), p.181

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34-6.33; = 0.007) and baseline Ang2 level ≥ 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level ≥ 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs.